FIELD: biotechnology.
SUBSTANCE: proposed is an antibody specifically binding CD152, including only heavy chains. The invention also relates to a nucleic acid, an expression vector, and a host cell for obtaining the antibody and to an application of the antibody for treating cancer and an autoimmune disease.
EFFECT: invention ensures effective inhibition of the signaling activity of CD152 with minimum adverse side effects.
27 cl, 15 dwg, 8 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PARTICLES CONJUGATED TO PEPTIDE | 2014 |
|
RU2813163C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| SPECIFIC ANTIBODIES TO PD-L1 AND METHODS FOR THEIR APPLICATION | 2017 |
|
RU2749109C2 |
| ANTI-PRE-S1 HBV ANTIBODIES | 2016 |
|
RU2739955C2 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2779489C2 |
| METHOD FOR PREVENTION AND TREATMENT OF CANCER METASTASES AND BONE LOSS CAUSED BY CANCER METASTASES | 2007 |
|
RU2470665C2 |
| BIOLOGICAL MATERIALS FOR MODULATING IMMUNE RESPONSES | 2017 |
|
RU2770060C2 |
| POLYPEPTIDE LINKER FOR PRODUCTION OF MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2776302C2 |
| CD3-SPECIFIC BINDING MOLECULES | 2020 |
|
RU2826453C2 |
| COMPOSITIONS AND METHODS FOR DEGRADATION OF IMPROPERLY PACKAGED PROTEINS | 2016 |
|
RU2761564C2 |
